Navigation Links
The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
Date:9/7/2009

Stemedica Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell research and manufacturing, announced the signing of an agreement today for its breakthrough stem cell and related technology. The Jordanian Stem Cell Company has signed a five year multi-million dollar agreement to purchase the technology from Stemedica's wholly-owned subsidiary, Stemedica International, S.A. The signing ceremony took place at the European Burns Association Congress in Lausanne, Switzerland.

San Diego, CA (PRWEB) September 7, 2009 -- Stemedica Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell research and manufacturing, announced the signing of an agreement today for its breakthrough stem cell and related technology. The Jordanian Stem Cell Company has signed a five year multi-million dollar agreement to purchase the technology from Stemedica's wholly-owned subsidiary, Stemedica International, S.A. The signing ceremony took place at the European Burns Association Congress in Lausanne, Switzerland.

"This is an important day for Stemedica International," said Frank Schuller, PhD, Stemedica International's Chairman. "This is a real testament to the quality and integrity of our products and the experience, dedication and professionalism of our team." The signing ceremony was attended by Mr. Sam Alkhass, Chief Executive Officer of the Jordanian Stem Cell Company as well as several representatives from Stemedica, including Dr. Schuller; Mark Tager, MD, Executive for Stemedica's Dermatological Operations; Alex Kharazi, MD, PhD, Stemedica's Vice President for Research and Manufacturing; and, Riccardo Nisato, MBA, PhD, Director of Manufacturing and Business Development, Stemedica International S.A.

"We are delighted to be working with Stemedica International," said Sam Alkhass. "Jordan has an excellent reputation as a provider of innovative and quality-driven medical treatment. It was fundamental to our company's future, and Jordan's reputation, that we find the best possible partner within the stem cell industry. We believe we have accomplished this objective by securing a long-term exclusive relationship with Stemedica International." Headquartered in Amman, The Jordanian Stem Cell Company is Chaired by His Royal Highness, Prince Asem Bin Nayef.

"We would like to thank the Jordanian Stem Cell Company and its Chairman, His Royal Highness, Prince Asem Bin Nayef for their vision and long-term commitment in bringing adult stem technology to Jordan," said Roger J. Howe, PhD, Chief Executive Officer for Stemedica International and Executive Chairman for Stemedica. "Our working relationship will not only provide significant medical advancements in treating the Citizens of Jordan, but will allow the country to continue to build on its growing reputation as a, "Center of Medical Excellence" for the entire region. We have a quality partner in The Jordanian Stem Cell Company and in the Country of Jordan and we look forward to growing these relationships."    

"Stemedica International will be providing our state-of-the-art stem cell technology to the Jordanian Stem Cell Company and will actively support their development and implementation of a Clinical Trial for burns," said Nikolai Tankovich, MD, PhD, Stemedica's President and Chief Medical Officer and Vice Chairman of Stemedica International. "We will work closely with the leadership of the Jordanian Stem Cell Company to secure all necessary governmental approvals for the Clinical Trial. The Trial is anticipated to begin sometime in the first quarter of 2010."

Stemedica International S.A. is a Lausanne, Switzerland-based, wholly owned subsidiary of Stemedica Cell Technologies, Inc. headquartered in San Diego, California. Stemedica is a developer and manufacturer of clinical grade stem cell products and is licensed by the State of California Food and Drug Branch.

About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human clinical trials. The company is currently developing regulatory pathways for stroke and wound repair. Stemedica is headquartered in San Diego, California.

For more information regarding Stemedica Cell Technologies, Inc. contact Dave McGuigan at dmcguigan (at) stemedica.com.

###

Read the full story at http://www.prweb.com/releases/stemedica-jordan/burn-stem-cell-trial/prweb2838964.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
3. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
4. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
5. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
6. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
7. NASA technology forms the basis for a new nanotechnology company
8. Solazyme, Inc. Selected by AlwaysOn as a GoingGreen 100 Top Private Company Award Winner
9. Abaxis to Present at the Sidoti & Company Sixth Annual San Francisco Institutional Investor Forum Conference
10. Monsanto Company Signs Share Subscription Agreement With Devgen
11. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
(Date:5/2/2016)... ... May 02, 2016 , ... Meister Media Worldwide launches ... look and added functionality give the agricultural world a taste of Meister Media ... in agriculture – from precision farming via satellites and Unmanned Aerial Vehicles (UAVs) ...
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design team has won multiple ... how bacterial properties can be applied to fabric and formed into living interfaces between ... response to humidity change. The team harvested Natto cells and applied them to fabric ...
(Date:4/29/2016)... 29, 2016 According to ... Research "Separation Systems for Commercial Biotechnology Market - ... Forecast 2015 - 2023", the separation systems for ... Mn in 2014 and is projected to expand ... 2023 to reach US$ 19,227.8 Mn in 2023. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced today ... via 510(k) for sale in the United States. These components expand the capabilities ... With one-level sales beginning in October of 2015, the company has seen significant ...
Breaking Biology Technology:
(Date:3/14/2016)... , March 14, 2016 NXTD ... growing mobile commerce market, announces the airing of a new ... starting the week of March 21 st .  The commercials ... including its popular Squawk on the Street show. --> ... on the growing mobile commerce market, announces the airing of ...
(Date:3/10/2016)... PUNE, India , March 10, 2016 ... to a new market research report "Identity and Access ... SSO, & Audit, Compliance, and Governance), by Organization Size, ... Forecast to 2020", published by MarketsandMarkets, The market is ... to USD 12.78 Billion by 2020, at a Compound ...
(Date:3/9/2016)... , March 9, 2016  Crossmatch ® , ... enrollment solutions, today announced the addition of smart ... Altus multi-factor authentication platform. New contextual and ... to step-up security where it,s needed most — ... Washington, DC . --> ...
Breaking Biology News(10 mins):